Telix Pharmaceuticals (NASDAQ:TLX) Sets New 12-Month Low – Here’s Why

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $6.31 and last traded at $6.3250, with a volume of 19070 shares traded. The stock had previously closed at $6.54.

Wall Street Analyst Weigh In

TLX has been the topic of a number of analyst reports. Wall Street Zen lowered Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday, January 27th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Price Performance

The stock’s fifty day moving average is $7.72 and its 200 day moving average is $9.39.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers grew its holdings in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. IHT Wealth Management LLC acquired a new position in Telix Pharmaceuticals during the 2nd quarter worth $213,000. Private Advisor Group LLC lifted its position in Telix Pharmaceuticals by 67.3% during the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after purchasing an additional 16,945 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $297,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Telix Pharmaceuticals in the 3rd quarter valued at about $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.